Alpha-synuclein (α-Syn) aggregation is known to be a causative factor in synucleinopathies, including Parkinson's disease and dementia with Lewy bodies, but the detailed mechanism and treatment remain unresolved. In addition, various cellular dysfunctions have been reported to occur in brain cells of patients with synucleinopathy. We are investigating the pharmacological effects of lysophospholipid (LPL) extracted from porcine liver enzyme degradation product (PLDP) on these cellular dysfunctions. PLDP is used in functional foods and has been reported to improve human cognitive function and inhibit intracellular α-Syn aggregation in previous studies. In this experiment, we use an α-Syn aggregating cell model in which an α-Syn stable expression line was generated using human neuroblastoma SK-N-SH and transfected with α-Syn seeds. This model was exposed to LPL and seed-dependent cytotoxicity was evaluated, and the ameliorative effect of LPL was confirmed. The purpose of this study is to verify whether LPL has an ameliorative effect on cellular dysfunction and to expand its potential as a novel therapeutic agent for synucleinopathy.